The efficacy and safety of TREVO stent in the treatment of acute ischemic stroke caused by brachial artery disease
Abstract
Objective To explore the efficacy and safety of TERVO stent in the treatment of acute ischemic stroke caused by brachialartery disease. Methods This retrospective study included 9 patients from March 2017 to September 2019 who suffered with acute ischemic stroke caused by brachial artery disease. Among them 5 cases suffered with middle cerebral artery (MCA) M2 occlusion, 2 cases with MCA M3 occlusion and 2 cases with posterior cerebral artery (PCA) P1 occlusion. All patients underwent thrombectomy by TREVO stent while 5 of them were also treated with intravenous thrombolysis in the Department of Vascular Intervention of Civil Aviation General Hospital. The vascular recanalization rate and postoperative bleeding rate were observed, meanwhile the National Institutes of Health Stroke Scale (NIHSS) was used before and 14 d after thrombectomy to assess the degree of neurological impairment. And the prognosis was assessed by the modified Rankin Scale (mRS) 90 d aftert heo peration. Results Among the 9 patients, 8 cases successfully completed the operation of thrombectomy, with a success rate of 8/9. mTICI grading immediately after thrombectomy, showed that 6 patients had grade level 3, 2 had level 2b and one had level 2a, while the rate of vascular recanalization was 8/9. Intracranial hemorrhage occurred in one case, massive cerebral infarction in one case and the clinical symptoms of the other 7 patients were significantly improved after treatment. NIHSS score at admission of 9 patients was 9.00 (7.50,11.00) while who scored 4.00 (2.50, 5.50) 14 d after thrombectomy. mRS ≤ 2 in 7 cases and >2 in 2 cases were followed up in 90d after thrombectomy, with a good prognosis in 7/9. Conclusions TREVO stent has favorable efficacy and safety in the treatment of acute ischemic stroke caused by brachial artery disease.
DOI:10.3969/j.issn.1672⁃6731.2020.08.014
Keywords
This work is licensed under a Creative Commons Attribution 3.0 License.